Identifying host genetic risk factors in the context of public health surveillance for invasive pneumococcal disease

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Lingappa, Jairam R ^a   Dumitrescu, Logan ^b   Zimmer, Shanta M ^d   Lynfield, Ruth ^e   McNicholl, Janet M ^f   Messonnier, Nancy E ^f   Whitney, Cynthia G ^f   Crawford, Dana C ^b,c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d EMORY UNIVERSITY   (United States)

^e MINNESOTA DEPARTMENT OF HEALTH   (United States)

^f CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; GENOMIC DNA; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 1BETA; INTERLEUKIN 4; MEMBRANE COFACTOR PROTEIN; MEMBRANE PROTEIN; PROTEIN IL1R1; PROTEIN PTAFR; PROTEIN SFTPA1; PROTEIN SFTPB; PROTEIN SFTPD; SURFACTANT PROTEIN D; UNCLASSIFIED DRUG; CD46 PROTEIN, HUMAN; DNA; IL1R1 PROTEIN, HUMAN; INTERLEUKIN 1 RECEPTOR TYPE I;

AFRICAN AMERICAN; ARTICLE; BLOOD ANALYSIS; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SURVEILLANCE; DNA EXTRACTION; DNA FLANKING REGION; EUROPEAN AMERICAN; FEASIBILITY STUDY; FEMALE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HOST PATHOGEN INTERACTION; HUMAN; IMMUNE RESPONSE; INFANT; INTRON; MAJOR CLINICAL STUDY; MALE; NEWBORN; PILOT STUDY; PNEUMOCOCCAL INFECTION; POPULATION RESEARCH; PRESCHOOL CHILD; PROTECTION; PUBLIC HEALTH; SINGLE NUCLEOTIDE POLYMORPHISM; BLOOD; CAUCASIAN; ETHNOLOGY; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETICS; HEALTH SURVEY; METHODOLOGY; MICROBIOLOGY; PHYSIOLOGY; RISK FACTOR; STREPTOCOCCUS PNEUMONIAE;

AFRICAN AMERICANS; ANTIGENS, CD46; CHILD, PRESCHOOL; COHORT STUDIES; DNA; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HOST-PATHOGEN INTERACTIONS; HUMANS; INFANT; INFANT, NEWBORN; MALE; PILOT PROJECTS; PNEUMOCOCCAL INFECTIONS; POLYMORPHISM, SINGLE NUCLEOTIDE; POPULATION SURVEILLANCE; PULMONARY SURFACTANT-ASSOCIATED PROTEIN D; RECEPTORS, INTERLEUKIN-1 TYPE I; RISK FACTORS; STREPTOCOCCUS PNEUMONIAE;

EID: 80051705230     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0023413     Document Type: Article

References (77)

1. Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, et al. (2003) Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 348: 1737-1746.
2. Robinson KA, Baughman W, Rothrock G, Barrett NL, Pass M, et al. (2001) Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: Opportunities for prevention in the conjugate vaccine era. JAMA 285: 1729-1735.
3. Centers for Disease Control and Prevention (2005) Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease-United States, 1998-2003. MMWR Morb Mortal Wkly Rep 54: 893-897.
4. Nuorti JP, Butler JC, Farley MM, Harrison LH, McGeer A, et al. (2000) Cigarette smoking and invasive pneumococcal disease. Active Bacterial Core Surveillance Team. N Engl J Med 342: 681-689.
5. Waterer GW, Wunderink RG, (2005) Genetic susceptibility to pneumonia. Clin Chest Med 26: 29-38.
6. Crawford DC, Zimmer SM, Morin CA, Messonnier NE, Lynfield R, et al. (2008) Integrating host genomics with surveillance for invasive bacterial diseases. Emerg Infect Dis 14: 1138-1140 PMCID: PMC2600343.
7. Jounblat R, Kadioglu A, Iannelli F, Pozzi G, Eggleton P, et al. (2004) Binding and agglutination of Streptococcus pneumoniae by human surfactant protein D (SP-D) vary between strains, but SP-D fails to enhance killing by neutrophils. Infect Immun 72: 709-716.
8. Forbes LR, Haczku A, (2010) SP-D and regulation of the pulmonary innate immune system in allergic airway changes. Clin Exp Allergy 40: 547-562.
9. Vandivier RW, Ogden CA, Fadok VA, Hoffmann PR, Brown KK, et al. (2002) Role of surfactant proteins A, D, and C1q in the clearance of apoptotic cells in vivo and in vitro: calreticulin and CD91 as a common collectin receptor complex. J Immunol 169: 3978-3986.
10. Gardai SJ, Xiao YQ, Dickinson M, Nick JA, Voelker DR, et al. (2003) By binding SIRPalpha or calreticulin/CD91, lung collectins act as dual function surveillance molecules to suppress or enhance inflammation. Cell 115: 13-23.
11. Ohya M, Nishitani C, Sano H, Yamada C, Mitsuzawa H, et al. (2006) Human pulmonary surfactant protein D binds the extracellular domains of Toll-like receptors 2 and 4 through the carbohydrate recognition domain by a mechanism different from its binding to phosphatidylinositol and lipopolysaccharide. Biochemistry 45: 8657-8664.
12. Sano H, Chiba H, Iwaki D, Sohma H, Voelker DR, et al. (2000) Surfactant proteins A and D bind CD14 by different mechanisms. J Biol Chem 275: 22442-22451.
13. Murakami S, Iwaki D, Mitsuzawa H, Sano H, Takahashi H, et al. (2002) Surfactant protein A inhibits peptidoglycan-induced tumor necrosis factor-alpha secretion in U937 cells and alveolar macrophages by direct interaction with toll-like receptor 2. J Biol Chem 277: 6830-6837.
14. LeVine AM, Whitsett JA, Gwozdz JA, Richardson TR, Fisher JH, et al. (2000) Distinct effects of surfactant protein A or D deficiency during bacterial infection on the lung. J Immunol 165: 3934-3940.
15. Liu CF, Rivere M, Huang HJ, Puzo G, Wang JY, (2010) Surfactant protein D inhibits mite-induced alveolar macrophage and dendritic cell activations through TLR signalling and DC-SIGN expression. Clin Exp Allergy 40: 111-122.
16. Chapman SJ, Khor CC, Vannberg FO, Frodsham A, Walley A, et al. (2007) IkappaB genetic polymorphisms and invasive pneumococcal disease. Am J Respir Crit Care Med 176: 181-187.
17. Chapman SJ, Khor CC, Vannberg FO, Rautanen A, Segal S, et al. (2010) NFKBIZ polymorphisms and susceptibility to pneumococcal disease in European and African populations. Genes Immun 11: 319-325.
18. Khor CC, Chapman SJ, Vannberg FO, Dunne A, Murphy C, et al. (2007) A Mal functional variant is associated with protection against invasive pneumococcal disease, bacteremia, malaria and tuberculosis. Nat Genet 39: 523-528.
19. IOM (Institute of Medicine) (2010) Challenges and Opportunities in Using Residual Newborn Screening Samples for Translational Research: Workshop Summary. Washington, DC.
20. Dumitrescu L, Ritchie MD, Brown-Gentry K, Pulley JM, Basford M, et al. (2010) Assessing the accuracy of observer-reported ancestry in a biorepository linked to electronic medical records. Genet Med 12: 648-650.
21. Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, et al. (2009) Finding the missing heritability of complex diseases. Nature 461: 747-753.
22. Schork NJ, Murray SS, Frazer KA, Topol EJ, (2009) Common vs. rare allele hypotheses for complex diseases. Curr Opin Genet Dev 19: 212-219.
23. Carlson CS, Eberle MA, Rieder MJ, Yi Q, Kruglyak L, et al. (2004) Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. Am J Hum Genet 74: 106-120.
24. Crawford DC, Akey DT, Nickerson DA, (2005) The patterns of natural variation in human genes. Annu Rev Genomics Hum Genet 6: 287-312.
25. Livingston RJ, von Niederhausern A, Jegga AG, Crawford DC, Carlson CS, et al. (2004) Pattern of sequence variation across 213 environmental response genes. Genome Res 14: 1821-1831.
26. Hinds DA, Stuve LL, Nilsen GB, Halperin E, Eskin E, et al. (2005) Whole-genome patterns of common DNA variation in three human populations. Science 307: 1072-1079.
27. International HapMap Consortium (2005) A haplotype map of the human genome. Nature 437: 1299-1320.
28. Shen R, Fan JB, Campbell D, Chang W, Chen J, et al. (2005) High-throughput SNP genotyping on universal bead arrays. Mutat Res 573: 70-82.
29. Hosono S, Faruqi AF, Dean FB, Du Y, Sun Z, et al. (2003) Unbiased whole-genome amplification directly from clinical samples. Genome Res 13: 954-964.
30. Falush D, Stephens M, Pritchard JK, (2003) Inference of population structure using multilocus genotype data: linked loci and correlated allele frequencies. Genetics 164: 1567-1587.
31. Pritchard JK, Stephens M, Donnelly P, (2000) Inference of population structure using multilocus genotype data. Genetics 155: 945-959.
32. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, et al. (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81: 559-575.
33. Pendergrass SA, Dudek SM, Crawford DC, Ritchie MD, (2010) Synthesis-View: visualization and interpretation of SNP association results for multi-cohort, multi-phenotype data and meta-analysis S BioData Min. 3: 10.
34. Johansson L, Rytkonen A, Bergman P, Albiger B, Kallstrom H, et al. (2003) CD46 in meningococcal disease. Science 301: 373-375.
35. Seya T, Hirano A, Matsumoto M, Nomura M, Ueda S, (1999) Human membrane cofactor protein (MCP, CD46): multiple isoforms and functions. Int J Biochem Cell Biol 31: 1255-1260.
36. Mold C, Nakayama S, Holzer TJ, Gewurz H, Du Clos TW, (1981) C-reactive protein is protective against Streptococcus pneumoniae infection in mice. J Exp Med 154: 1703-1708.
37. Mold C, Rodic-Polic B, Du Clos TW, (2002) Protection from Streptococcus pneumoniae infection by C-reactive protein and natural antibody requires complement but not Fc gamma receptors. J Immunol 168: 6375-6381.
38. Yother J, Volanakis JE, Briles DE, (1982) Human C-reactive protein is protective against fatal Streptococcus pneumoniae infection in mice. J Immunol 128: 2374-2376.
39. van der Pol WL, Huizinga TW, Vidarsson G, van der Linden MW, Jansen MD, et al. (2001) Relevance of Fcgamma receptor and interleukin-10 polymorphisms for meningococcal disease. J Infect Dis 184: 1548-1555.
40. Yee AM, Ng SC, Sobel RE, Salmon JE, (1997) Fc gammaRIIA polymorphism as a risk factor for invasive pneumococcal infections in systemic lupus erythematosus. Arthritis Rheum 40: 1180-1182.
41. Picard C, Puel A, Bonnet M, Ku CL, Bustamante J, et al. (2003) Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science 299: 2076-2079.
42. Letiembre M, Echchannaoui H, Ferracin F, Rivest S, Landmann R, (2005) Toll-like receptor-2 deficiency is associated with enhanced brain TNF gene expression during pneumococcal meningitis. J Neuroimmunol 168: 21-33.
43. Hibberd ML, Sumiya M, Summerfield JA, Booy R, Levin M, (1999) Association of variants of the gene for mannose-binding lectin with susceptibility to meningococcal disease. Meningococcal Research Group. Lancet 353: 1049-1053.
44. Roy S, Knox K, Segal S, Griffiths D, Moore CE, et al. (2002) MBL genotype and risk of invasive pneumococcal disease: a case-control study. Lancet 359: 1569-1573.
45. Albiger B, Sandgren A, Katsuragi H, Meyer-Hoffert U, Beiter K, et al. (2005) Myeloid differentiation factor 88-dependent signalling controls bacterial growth during colonization and systemic pneumococcal disease in mice. Cell Microbiol 7: 1603-1615.
46. Hartshorn KL, Crouch E, White MR, Colamussi ML, Kakkanatt A, et al. (1998) Pulmonary surfactant proteins A and D enhance neutrophil uptake of bacteria. Am J Physiol 274: L958-969.
47. Lin Z, Pearson C, Chinchilli V, Pietschmann SM, Luo J, et al. (2000) Polymorphisms of human SP-A, SP-B, and SP-D genes: association of SP-B Thr131Ile with ARDS. Clin Genet 58: 181-191.
48. Echchannaoui H, Bachmann P, Letiembre M, Espinosa M, Landmann R, (2005) Regulation of Streptococcus pneumoniae distribution by Toll-like receptor 2 in vivo. Immunobiology 210: 229-236.
49. Albiger B, Dahlberg S, Sandgren A, Wartha F, Beiter K, et al. (2007) Toll-like receptor 9 acts at an early stage in host defence against pneumococcal infection. Cell Microbiol 9: 633-644.
50. Yamamoto N, Kawakami K, Kinjo Y, Miyagi K, Kinjo T, et al. (2004) Essential role for the p40 subunit of interleukin-12 in neutrophil-mediated early host defense against pulmonary infection with Streptococcus pneumoniae: involvement of interferon-gamma. Microbes Infect 6: 1241-1249.
51. Read RC, Cannings C, Naylor SC, Timms JM, Maheswaran R, et al. (2003) Variation within genes encoding interleukin-1 and the interleukin-1 receptor antagonist influence the severity of meningococcal disease. Ann Intern Med 138: 534-541.
52. Fang XM, Schroder S, Hoeft A, Stuber F, (1999) Comparison of two polymorphisms of the interleukin-1 gene family: interleukin-1 receptor antagonist polymorphism contributes to susceptibility to severe sepsis. Crit Care Med 27: 1330-1334.
53. Chen Q, Sen G, Snapper CM, (2006) Endogenous IL-1R1 signaling is critical for cognate CD4+ T cell help for induction of in vivo type 1 and type 2 antipolysaccharide and antiprotein Ig isotype responses to intact Streptococcus pneumoniae, but not to a soluble pneumococcal conjugate vaccine. J Immunol 177: 6044-6051.
54. Emonts M, Veenhoven RH, Wiertsema SP, Houwing-Duistermaat JJ, Walraven V, et al. (2007) Genetic polymorphisms in immunoresponse genes TNFA, IL6, IL10, and TLR4 are associated with recurrent acute otitis media. Pediatrics 120: 814-823.
55. Schluter B, Raufhake C, Erren M, Schotte H, Kipp F, et al. (2002) Effect of the interleukin-6 promoter polymorphism (-174 G/C) on the incidence and outcome of sepsis. Crit Care Med 30: 32-37.
56. Schmeck B, Zahlten J, Moog K, van Laak V, Huber S, et al. (2004) Streptococcus pneumoniae-induced p38 MAPK-dependent phosphorylation of RelA at the interleukin-8 promotor. J Biol Chem 279: 53241-53247.
57. Gordon SB, Jarman ER, Kanyanda S, French N, Pridmore AC, et al. (2005) Reduced interleukin-8 response to Streptococcus pneumoniae by alveolar macrophages from adults with HIV/AIDS. AIDS 19: 1197-1200.
58. Westendorp RG, Langermans JA, Huizinga TW, Elouali AH, Verweij CL, et al. (1997) Genetic influence on cytokine production and fatal meningococcal disease. Lancet 349: 170-173.
59. Schaaf BM, Boehmke F, Esnaashari H, Seitzer U, Kothe H, et al. (2003) Pneumococcal septic shock is associated with the interleukin-10-1082 gene promoter polymorphism. Am J Respir Crit Care Med 168: 476-480.
60. Gallagher PM, Lowe G, Fitzgerald T, Bella A, Greene CM, et al. (2003) Association of IL-10 polymorphism with severity of illness in community acquired pneumonia. Thorax 58: 154-156.
61. Ling E, Feldman G, Dagan R, Mizrachi-Nebenzahl Y, (2003) Cytokine mRNA expression in pneumococcal carriage, pneumonia, and sepsis in young mice. J Infect Dis 188: 1752-1756.
62. Lynch JM, Briles DE, Metzger DW, (2003) Increased protection against pneumococcal disease by mucosal administration of conjugate vaccine plus interleukin-12. Infect Immun 71: 4780-4788.
63. Lauw FN, Branger J, Florquin S, Speelman P, van Deventer SJ, et al. (2002) IL-18 improves the early antimicrobial host response to pneumococcal pneumonia. J Immunol 168: 372-378.
64. Paterson GK, Blue CE, Mitchell TJ, (2005) Role of interleukin-18 in experimental infections with Streptococcus pneumoniae. J Med Microbiol 54: 323-326.
65. Zwijnenburg PJ, van der Poll T, Florquin S, Akira S, Takeda K, et al. (2003) Interleukin-18 gene-deficient mice show enhanced defense and reduced inflammation during pneumococcal meningitis. J Neuroimmunol 138: 31-37.
66. Stuber F, Petersen M, Bokelmann F, Schade U, (1996) A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-alpha concentrations and outcome of patients with severe sepsis. Crit Care Med 24: 381-384.
67. Mira JP, Cariou A, Grall F, Delclaux C, Losser MR, et al. (1999) Association of TNF2, a TNF-alpha promoter polymorphism, with septic shock susceptibility and mortality: a multicenter study. JAMA 282: 561-568.
68. McGuire W, Hill AV, Allsopp CE, Greenwood BM, Kwiatkowski D, (1994) Variation in the TNF-alpha promoter region associated with susceptibility to cerebral malaria. Nature 371: 508-510.
69. Bernard GR, (2003) Drotrecogin alfa (activated) (recombinant human activated protein C) for the treatment of severe sepsis. Crit Care Med 31: S85-93.
70. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, et al. (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344: 699-709.
71. Cundell DR, Gerard NP, Gerard C, Idanpaan-Heikkila I, Tuomanen EI, (1995) Streptococcus pneumoniae anchor to activated human cells by the receptor for platelet-activating factor. Nature 377: 435-438.
72. Geishofer G, Binder A, Muller M, Zohrer B, Resch B, et al. (2005) 4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene in children with systemic meningococcaemia. Eur J Pediatr 164: 486-490.
73. Westendorp RG, Hottenga JJ, Slagboom PE, (1999) Variation in plasminogen-activator-inhibitor-1 gene and risk of meningococcal septic shock. Lancet 354: 561-563.
74. Jeurissen A, Wuyts G, Kasran A, Ramdien-Murli S, Blanckaert N, et al. (2004) The human antibody response to pneumococcal capsular polysaccharides is dependent on the CD40-CD40 ligand interaction. Eur J Immunol 34: 850-858.
75. Boudewijns M, Jeurissen A, Wuyts M, Moens L, Boon L, et al. (2005) Blockade of CTLA-4 (CD152) enhances the murine antibody response to pneumococcal capsular polysaccharides. J Leukoc Biol.
76. Matute-Bello G, Liles WC, Frevert CW, Dhanireddy S, Ballman K, et al. (2005) Blockade of the Fas/FasL system improves pneumococcal clearance from the lungs without preventing dissemination of bacteria to the spleen. J Infect Dis 191: 596-606.
77. Paul R, Angele B, Sporer B, Pfister HW, Koedel U, (2004) Inflammatory response during bacterial meningitis is unchanged in Fas- and Fas ligand-deficient mice. J Neuroimmunol 152: 78-82.